Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic.

Abstract

Purpose Multidisciplinary management improves complex treatment decision making in cancer care, but its impact for bladder cancer (BC) has not been documented. Although radical cystectomy (RC) currently is viewed as the standard of care for muscle-invasive bladder cancer (MIBC), radiotherapy-based, bladder-sparing trimodal therapy (TMT) that combines transurethral resection of bladder tumor, chemotherapy for radiation sensitization, and external beam radiotherapy has emerged as a valid treatment option. In the absence of randomized studies, this study compared the oncologic outcomes between patients treated with RC or TMT by using a propensity score matched-cohort analysis. Methods Data from patients treated in a multidisciplinary bladder cancer clinic (MDBCC) from 2008 to 2013 were reviewed retrospectively. Those who received TMT for MIBC were identified and matched (for sex, cT and cN stage, Eastern Cooperative Oncology Group status, Charlson comorbidity score, treatment date, age, carcinoma in situ status, and hydronephrosis) with propensity scores to patients who underwent RC. Overall survival and disease-specific survival (DSS) were assessed with Cox proportional hazards modeling and a competing risk analysis, respectively. Results A total of 112 patients with MIBC were included after matching (56 who had been treated with TMT, and 56 who underwent RC). The median age was 68.0 years, and 29.5% had stage cT3/cT4 disease. At a median follow-up of 4.51 years, there were 20 deaths (35.7%) in the RC group (13 as a result of BC) and 22 deaths (39.3%) in the TMT group (13 as a result of BC). The 5-year DSS rate was 73.2% and 76.6% in the RC and TMT groups, respectively ( P = .49). Salvage cystectomy was performed in 6 (10.7%) of 56 patients who received TMT. Conclusion In the setting of a MDBCC, TMT yielded survival outcomes similar to those of matched patients who underwent RC. Appropriately selected patients with MIBC should be offered the opportunity to discuss various treatment options, including organ-sparing TMT.

• Authors: Girish S Kulkarni, Thomas Hermanns, Yanliang Wei, Bimal Bhindi, Raj Satkunasivam, Paul Athanasopoulos, Peter J Bostrom, Cynthia Kuk, Kathy Li, Arnoud J Templeton, Srikala S Sridhar, Theodorus H van der Kwast, Peter Chung, Robert G Bristow, Michael Milosevic, Padraig Warde, Neil E Fleshner, Michael A S Jewett, Shaheena Bashir, Alexandre R Zlotta
• Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (J Clin Oncol) Vol. 35 Issue 20 Pg. 2299-2305 (Jul 10 2017) ISSN: 1527-7755 [Electronic] United States
• PMID: 28410011 (Publication Type: Comparative Study, Journal Article)

Chemical References

• Antineoplastic Agents

Topics

• Adult
• Aged
• Aged, 80 and over
• Antineoplastic Agents (therapeutic use)
• Carcinoma (pathology, therapy)
• Combined Modality Therapy
• Cystectomy
• Disease-Free Survival
• Female
• Humans
• Male
• Middle Aged
• Neoplasm Invasiveness
• Neoplasm Staging
• Organ Sparing Treatments
• Patient Care Team
• Propensity Score
• Radiotherapy
• Retrospective Studies
• Survival Rate
• Urinary Bladder
• Urinary Bladder Neoplasms (pathology, therapy)